Development of Inducible Hypoimmunogenic iPSC-Derived β-Cells for Immune- Evasive Cell Replacement Therapies in Type 1 Diabetes (360G-Wellcome-337452_Z_25_Z)
Type 1 diabetes (T1D) results from autoimmune-mediated destruction of insulin- producing pancreatic β-cells, leading to chronic insulin deficiency. While islet transplantation offers temporary glycaemic control, its clinical application remains limited by donor scarcity and immune rejection. A promising alternative involves generating β-cells from induced pluripotent stem cells (iPSCs), which can differentiate into insulin-producing cells capable of reversing diabetes in preclinical models. However, a major barrier to clinical success remains the poor survival of SC-islets post- transplantation, primarily due to hypoxia, inflammation and immune-mediated mechanisms. To circumvent these challenges, immune-evasive strategies have been developed, including the use of genome editing to generate hypoimmunogenic SC-islets. Permanent deletion of genes involved in antigen presentation or overexpression of immune-regulatory molecules can reduce immune recognition. However, these approaches carry concerns regarding safety, especially where permanent modifications may impair immune surveillance. In this project, we propose a modular approach using doxycycline (Dox)-inducible transgenes in iPSCs to regulate immune-evasive factors temporarily. We aim to generate inducible hypoimmunogenic iPSC lines, which, once differentiated to pancreatic β-cells, will be validated in vivo. By generating functional, hypoimmunogenic iPSC-derived β-cells, this project aims to advance the safety and efficacy of cell replacement therapies for T1D.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.